Personalis Stock Falls on Preliminary 4Q Results

Dow Jones01-09

By Emon Reiser

Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday.

The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date.

Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect.

The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period.

"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory," said Chief Executive Chris Hall. "With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy."

Write to Emon Reiser at emon.reiser@wsj.com

(END) Dow Jones Newswires

January 08, 2026 14:33 ET (19:33 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602539714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602539714","market":"sg","top_or_hot":-1,"title":"Personalis Stock Falls on Preliminary 4Q Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Shares for <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n</p>\n<p>\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n</p>\n<p>\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n</p>\n<p>\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n</p>\n<p>\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis Stock Falls on Preliminary 4Q Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis Stock Falls on Preliminary 4Q Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 03:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Emon Reiser \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Shares for <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n</p>\n<p>\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n</p>\n<p>\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n</p>\n<p>\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n</p>\n<p>\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Emon Reiser at emon.reiser@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602539714","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602539714","pubTimestamp":1767900780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday.The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date.Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect.The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period.\"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","PSNL":"Personalis"},"translate_title":"Personalis股价因第四季度初步业绩而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1.5},"content_text":"By Emon Reiser \n\n\n \n\n\n   Shares for Personalis fell despite ample cash on hand and a surge in clinical test revenue, according to a preliminary fourth-quarter report released Thursday. \n\n\n  The stock declined 12.6% to $8.17 a share. Despite the intraday decline, shares are up 2.7% year to date. \n\n\n  Personalis said it expects between $17 million and $18 million in fourth-quarter revenue, on par with the $17.5 million analysts expect. \n\n\n  The company said its preliminary clinical test revenue for the quarter is about $900,000 from 6,183 clinical tests in the fourth quarter, compared with about $200,000 in clinical test revenue in the year-ago period. \n\n\n  \"Securing Medicare coverage for breast cancer surveillance in the fourth quarter was a pivotal milestone that transforms our commercial trajectory,\" said Chief Executive Chris Hall. \"With a fortified balance sheet of [about] $240 million of cash, we enter 2026 with the capital and the clinical evidence required to expand our sales footprint, secure reimbursement coverage for additional indications, and continue to execute on our Win-in-MRD strategy.\" \n\n\n \n\n\n   Write to Emon Reiser at emon.reiser@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 14:33 ET (19:33 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602539714","isCrawlerRequest":true}